Keith C. Hayes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Keith C. Hayes has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Dalton L. Wolfe
Department of Physical Medicine & Rehabilitation
2 shared publicationsPatrick J. Potter
2 shared publicationsRon Cohen
Acorda therapeutics inc
2 shared publicationsAndrei Krassioukov
1 shared publicationAndrew R Blight
Acorda therapeutics inc
1 shared publicationAndrew R. Blight
1 shared publication
Latest Publications
- Open Access
- 1 April 2011
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. 7 (1) , 229-239
Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis
Dalfampridine extended release (ER) 10 mg is an oral tablet form of the potassium (K+) channel-blocking compounded dalfampridine, also known as fampridine, and chemically 4-aminopyridine or 4-AP, which received regulatory approval in the United States for the treatment of walking in patients with multiple sclerosis (MS) in January 2010. Two pivotal Phase 3 clinical trials demonstrated significant improvements in walking in patients with the four primary forms of MS following administration of dalfampridine ER tablets 10 mg twice daily. The drug is thought to act by restoring conduction in focally demyelinated axons and by enhancing neurotransmission, thereby leading to improved neurological function. This review describes how dalfampridine represents a new pharmacotherapeutic approach to the clinical management of mobility impairment. It describes the mechanism of action and chemistry of dalfampridine ER, its pharmacokinetics, tolerability, and side effects, and the outcomes of multicenter trials showing its efficacy in improving walking speed. Clinician and patient global assessments, as well as patient self-assessment of the impact of MS on their gait disability, confirm clinically relevant benefit from the therapy. Patients tolerate the drug well and their improvement in terms of household and community ambulation, inferred from analysis of pooled data from several studies, is likely to translate into benefits in the performance of instrumental activities of daily living and a reduction in the neuropsychiatric burden of disease.
- 1 April 2011
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. 7 (1) , 229-239
Open AccessImpact of extended-release dalfampridine on walking ability in patients with multiple sclerosis
Dalfampridine extended release (ER) 10 mg is an oral tablet form of the potassium (K+) channel-blocking compounded dalfampridine, also known as fampridine, and chemically 4-aminopyridine or 4-AP, which received regulatory approval in the United States for the treatment of walking in patients with multiple sclerosis (MS) in January 2010. Two pivotal Phase 3 clinical trials demonstrated significant improvements in walking in patients with the four primary forms of MS following administration of dalfampridine ER tablets 10 mg twice daily. The drug is thought to act by restoring conduction in focally demyelinated axons and by enhancing neurotransmission, thereby leading to improved neurological function. This review describes how dalfampridine represents a new pharmacotherapeutic approach to the clinical management of mobility impairment. It describes the mechanism of action and chemistry of dalfampridine ER, its pharmacokinetics, tolerability, and side effects, and the outcomes of multicenter trials showing its efficacy in improving walking speed. Clinician and patient global assessments, as well as patient self-assessment of the impact of MS on their gait disability, confirm clinically relevant benefit from the therapy. Patients tolerate the drug well and their improvement in terms of household and community ambulation, inferred from analysis of pooled data from several studies, is likely to translate into benefits in the performance of instrumental activities of daily living and a reduction in the neuropsychiatric burden of disease.
- 7 December 2009
- Published by Taylor & Francis in Disability and Rehabilitation
- Vol. 32 (5) , 424-428
On the interaction of disability and aging: Accelerated degradation models and their influence on projections of future care needs and costs for personal injury litigation
Purpose. Accelerated degradation models are emerging as ways to characterize the interaction between disability and the functional decline of aging and to provide insights about the processes of aging with disability. Typically the models employ sophisticated mathematical treatments that are beyond the scope of many clinicians, lawyers, and others who might benefit from the information they contain. The purpose of this report is to characterize some rudimentary features of the models, in more readily understandable language, and illustrate how understanding of the underlying constructs can influence decisions regarding resource allocation and other projections of future care needs. Methods. A literature review of longitudinal aging and disability studies was completed and simplified mathematical modeling undertaken, with hypothetical data, to illustrate various outcomes of the interaction of disability with the functional decline of aging. A specific example, drawn from personal injury litigation, i.e. projection of future care costs, was used to illustrate the practical applicability of this conceptual model. Conclusion. Awareness of the accelerated functional decline brought about by the superimposition of age-related functional losses on pre-existing disability reveals a need to provide for aids and personnel supports at an earlier age than might be expected because of the multiplicative interaction and the inadequacy of functional reserves to compensate for the disability.
- 7 December 2009
- Published by Taylor & Francis in Disability and Rehabilitation
- Vol. 32 (5) , 424-428
On the interaction of disability and aging: Accelerated degradation models and their influence on projections of future care needs and costs for personal injury litigation
Purpose. Accelerated degradation models are emerging as ways to characterize the interaction between disability and the functional decline of aging and to provide insights about the processes of aging with disability. Typically the models employ sophisticated mathematical treatments that are beyond the scope of many clinicians, lawyers, and others who might benefit from the information they contain. The purpose of this report is to characterize some rudimentary features of the models, in more readily understandable language, and illustrate how understanding of the underlying constructs can influence decisions regarding resource allocation and other projections of future care needs. Methods. A literature review of longitudinal aging and disability studies was completed and simplified mathematical modeling undertaken, with hypothetical data, to illustrate various outcomes of the interaction of disability with the functional decline of aging. A specific example, drawn from personal injury litigation, i.e. projection of future care costs, was used to illustrate the practical applicability of this conceptual model. Conclusion. Awareness of the accelerated functional decline brought about by the superimposition of age-related functional losses on pre-existing disability reveals a need to provide for aids and personnel supports at an earlier age than might be expected because of the multiplicative interaction and the inadequacy of functional reserves to compensate for the disability.
- 1 May 2007
- Published by Taylor & Francis in Expert Review of Neurotherapeutics
- Vol. 7 (5) , 453-461
Fampridine-SR for multiple sclerosis and spinal cord injury
Fampridine-SR is a sustained-release tablet form of the K(+) channel-blocking compound 4-aminopyridine that has been shown to restore conduction in focally demyelinated axons, to enhance synaptic transmission in many types of neurons and to potentiate muscle contraction. The present review describes the mechanism of action and chemistry of Fampridine-SR, its pharmacokinetics and safety, and the outcomes of clinical trials of its safety and efficacy for enhancing neuromuscular function in patients with multiple sclerosis or spinal cord injury. Randomized clinical trials completed to date indicate that this form of K(+) channel blockade may be useful for the improvement of walking ability in patients with multiple sclerosis.
- 1 May 2007
- Published by Taylor & Francis in Expert Review of Neurotherapeutics
- Vol. 7 (5) , 453-461
Fampridine-SR for multiple sclerosis and spinal cord injury
Fampridine-SR is a sustained-release tablet form of the K(+) channel-blocking compound 4-aminopyridine that has been shown to restore conduction in focally demyelinated axons, to enhance synaptic transmission in many types of neurons and to potentiate muscle contraction. The present review describes the mechanism of action and chemistry of Fampridine-SR, its pharmacokinetics and safety, and the outcomes of clinical trials of its safety and efficacy for enhancing neuromuscular function in patients with multiple sclerosis or spinal cord injury. Randomized clinical trials completed to date indicate that this form of K(+) channel blockade may be useful for the improvement of walking ability in patients with multiple sclerosis.
- Open Access
- 1 December 2004
- Published by Wiley in CNS Drug Reviews
- Vol. 10 (4) , 295-316
The Use of 4‐Aminopyridine (Fampridine) in Demyelinating Disorders
4‐Aminopyridine (4‐AP or fampridine) is a potassium channel‐blocking agent that has been shown to restore conduction in focally demyelinated axons. A sustained‐release matrix tablet form of 4‐AP (fampridine‐SR) is currently undergoing multicenter clinical trials in patients with multiple sclerosis or chronic spinal cord injury. This review describes the pharmacology and mechanisms of action of 4‐AP, its pharmacokinetics in human subjects, and the outcomes of clinical trials employing either immediate‐release or sustained‐release formulations of the drug. The randomized clinical trials that have been completed to date indicate that K+channel blockade may prove to be a useful strategy for ameliorating central conduction deficits due to demyelination. Diverse neurological gains have been reported for both motor and sensory domains. At the present time, however, the clinical trials have not provided sufficiently robust or definitive evidence of efficacy to gain regulatory approval for the symptomatic management of patients with either multiple sclerosis or spinal cord injury.
- 1 December 2004
- Published by Wiley in CNS Drug Reviews
- Vol. 10 (4) , 295-316
Open AccessThe Use of 4‐Aminopyridine (Fampridine) in Demyelinating Disorders
4‐Aminopyridine (4‐AP or fampridine) is a potassium channel‐blocking agent that has been shown to restore conduction in focally demyelinated axons. A sustained‐release matrix tablet form of 4‐AP (fampridine‐SR) is currently undergoing multicenter clinical trials in patients with multiple sclerosis or chronic spinal cord injury. This review describes the pharmacology and mechanisms of action of 4‐AP, its pharmacokinetics in human subjects, and the outcomes of clinical trials employing either immediate‐release or sustained‐release formulations of the drug. The randomized clinical trials that have been completed to date indicate that K+channel blockade may prove to be a useful strategy for ameliorating central conduction deficits due to demyelination. Diverse neurological gains have been reported for both motor and sensory domains. At the present time, however, the clinical trials have not provided sufficiently robust or definitive evidence of efficacy to gain regulatory approval for the symptomatic management of patients with either multiple sclerosis or spinal cord injury.
- 1 January 2004
- Published by Elsevier in Archives of Physical Medicine and Rehabilitation
- Vol. 85 (1) , 29-34
Pharmacokinetics and safety of multiple oral doses of sustained-release 4-aminopyridine (fampridine-sr) in subjects with chronic, incomplete spinal cord injury 11A commercial party with a direct financial interest in the results of the research supporting this article has conferred or will confer a financial benefit on the author or 1 or more of the authors.
- 1 January 2004
- Published by Elsevier in Archives of Physical Medicine and Rehabilitation
- Vol. 85 (1) , 29-34
Pharmacokinetics and safety of multiple oral doses of sustained-release 4-aminopyridine (fampridine-sr) in subjects with chronic, incomplete spinal cord injury 11A commercial party with a direct financial interest in the results of the research supporting this article has conferred or will confer a financial benefit on the author or 1 or more of the authors.
- 1 July 2003
- Published by Wolters Kluwer Health in Clinical Neuropharmacology
- Vol. 26 (4) , 185-192
Pharmacokinetic Studies of Single and Multiple Oral Doses of Fampridine-SR (Sustained-Release 4-Aminopyridine) in Patients With Chronic Spinal Cord Injury
Fampridine (4-aminopyridine) is a potassium channel blocking agent that restores conduction in demyelinated axons and improves neurologic function in patients with chronic spinal cord injury (SCI). Based on the pharmacokinetic profile of orally administered fampridine, multiple daily doses (4 or more) would need to be taken to sustain its therapeutic effects. Two studies were conducted to determine the pharmacokinetics and safety profile of an oral, sustained-release (SR) formulation of fampridine (fampridine-SR, 10–25 mg) administered as a single dose (n = 14) and twice daily for 1 week (n = 16) in patients with chronic, incomplete SCI. Mean plasma concentrations and area under the plasma concentration–time curve were proportional to the dose administered, whereas other pharmacokinetic parameters were independent of dose. Fampridine-SR was absorbed slowly (peak plasma concentration shortly after dosing, 2.6–3.7 hours) and eliminated (plasma half-life, 5.6–7.6 hours), and reached steady state after 4 days of twice-daily administration. Fampridine-SR was well tolerated, with only mild to moderate adverse events reported, and no serious adverse events. The extended plasma half-life of fampridine-SR allows convenient twice-daily dosing. Clinical trials designed to assess neurologic and functional improvement using fampridine-SR in patients with chronic SCI are currently underway.
- 1 July 2003
- Published by Wolters Kluwer Health in Clinical Neuropharmacology
- Vol. 26 (4) , 185-192
Pharmacokinetic Studies of Single and Multiple Oral Doses of Fampridine-SR (Sustained-Release 4-Aminopyridine) in Patients With Chronic Spinal Cord Injury
Fampridine (4-aminopyridine) is a potassium channel blocking agent that restores conduction in demyelinated axons and improves neurologic function in patients with chronic spinal cord injury (SCI). Based on the pharmacokinetic profile of orally administered fampridine, multiple daily doses (4 or more) would need to be taken to sustain its therapeutic effects. Two studies were conducted to determine the pharmacokinetics and safety profile of an oral, sustained-release (SR) formulation of fampridine (fampridine-SR, 10–25 mg) administered as a single dose (n = 14) and twice daily for 1 week (n = 16) in patients with chronic, incomplete SCI. Mean plasma concentrations and area under the plasma concentration–time curve were proportional to the dose administered, whereas other pharmacokinetic parameters were independent of dose. Fampridine-SR was absorbed slowly (peak plasma concentration shortly after dosing, 2.6–3.7 hours) and eliminated (plasma half-life, 5.6–7.6 hours), and reached steady state after 4 days of twice-daily administration. Fampridine-SR was well tolerated, with only mild to moderate adverse events reported, and no serious adverse events. The extended plasma half-life of fampridine-SR allows convenient twice-daily dosing. Clinical trials designed to assess neurologic and functional improvement using fampridine-SR in patients with chronic SCI are currently underway.
- 1 November 2002
- Published by Elsevier in Archives of Physical Medicine and Rehabilitation
- Vol. 83 (11) , 1612-1619
Clinical and electrophysiologic correlates of quantitative sensory testing in patients with incomplete spinal cord injury
- 1 November 2002
- Published by Elsevier in Archives of Physical Medicine and Rehabilitation
- Vol. 83 (11) , 1612-1619
Clinical and electrophysiologic correlates of quantitative sensory testing in patients with incomplete spinal cord injury